NKTR-181
Jan 16, 2020
Thumbs down to NKTR-181, Lilly expands its insulin armamentarium
The US FDA has voted down Nektar Therapeutics’ opioid painkiller NKTR-181, designed to treat lower back pain. The FDA’s Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee unanimously has decided not to recommend the use of the painkiller, ta...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
